NYSE · Medical - Diagnostics & Research

QGEN (QGEN) Stock

$42.28 +2.92% NYSE: QGEN Healthcare

Valuation

MetricValue
Price$42.28
Market Cap$8.72B
P/E Ratio16.78
P/B Ratio1.87
P/S Ratio3.36
EPS (TTM)$2.04
52-Week High$57.82
52-Week Low$32.53
Dividend Yield0.73%

Financials & Margins

MetricValue
ROE11.25%
ROA6.75%
ROCE13.76%
Gross Margin24.88%
Operating Margin24.88%
Net Margin19.16%
Debt/Equity0.49
Current Ratio3.90

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.3B$2.1B$2.0B$2.0B$2.1B
Operating Profit$630.0M$531.0M$410.0M$98.0M$520.0M
Net Profit$513.0M$423.0M$341.0M$84.0M$425.0M
EPS$2.47$2.05$1.65$0.38$2.04
Op Margin28.0%24.8%20.9%4.9%24.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.1B$6.3B$6.1B$5.7B$6.3B
Total Liabilities$3.0B$2.8B$2.3B$2.1B$2.5B
Cash$881.0M$731.0M$668.0M$664.0M$839.0M
Borrowings$2.1B$2.0B$1.7B$1.6B$1.7B

Latest News

KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen Simply Wall St. · Jul 22, 2026 Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption Accelerate GlobeNewswire · Jul 17, 2026 QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak Business Wire · Jul 15, 2026 QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast Business Wire · Jul 15, 2026 Qiagen Launches QIAstat-Dx Bloodstream Infection Testing in Europe MT Newswires · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$639.0M$715.0M$459.0M$674.0M$654.0M
Investing Cash Flow$-409.0M$-876.0M$-250.0M$-416.0M$-506.0M
Financing Cash Flow$-117.0M$-17.0M$3.0M$-316.0M$-333.0M
Net Cash Flow$283.0M$-150.0M$-63.0M$-5.0M$175.0M
Free Cash Flow$432.0M$566.0M$297.0M$506.0M$453.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA11.02
FCF Yield5.82%
Quick Ratio2.57
Interest Coverage15.76
Return 1Y-14.91%
Return 3Y-11.93%
Return 5Y-20.01%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGNAlign Technology, Inc. $169.29 +1.36% 27.86 $12.12B 0.00%
BAXBaxter International Inc. $23.18 +3.46% 11.25 $11.97B 0.88%
BMRN $60.00 -0.04% 41.31 $11.60B 0.00%
CRL $232.51 -0.90% -54.59 $11.20B 0.00%
ENSG $181.35 +1.84% 25.83 $10.60B 0.16%

About QGEN

QGEN is led by CEO Thierry Bernard, employs 5,736 people, headquartered in Venlo, NL, publicly traded since 1996.

QGEN stock trades at $42.28 with a market capitalization of $8.72B. The stock is valued at a price-to-earnings (P/E) ratio of 16.78, price-to-book of 1.87, price-to-sales of 3.36. Over the past 52 weeks the stock has ranged between $32.53 and $57.82, and currently trades 26.9% below its 52-week high. It pays a dividend yielding 0.73%.

On profitability, QGEN generates a return on equity (ROE) of 11.25%, return on capital employed of 13.76%, an operating margin of 24.88%, a net profit margin of 19.16%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides